Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma.
Drug resistance remains a significant obstacle to improving therapeutic outcome following treatment for malignant lymphoma. Eliminating P-glycoprotein as one mechanism of drug resistance may select for alternative, non-P-glycoprotein mechanisms of drug resistance. Understanding these alternative forms of drug resistance is imperative in order to improve therapy for NHL.
Dalton
W S
WS
H. Lee Moffitt Cancer Center, University of South Florida, Tampa, USA.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D017209:Apoptosis; D004260:DNA Repair; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D004250:DNA Topoisomerases, Type II